Garlic Metabolite Boosts Muscle Function in Aged Mice
S1PC activated an adipose-to-brain signaling pathway and improved frailty and muscle-force measures in aged male mice, while the human experiment measured only a short-term biomarker response.
The 60-second version
S1PC activated a white-fat-to-hypothalamus pathway and improved frailty and muscle-force measures in aged mice.
Key points
- S1PC promoted LKB1 complex formation, SIRT1 phosphorylation and eNAMPT-vesicle secretion from white adipose tissue.
- Fat-derived eNAMPT reached the hypothalamus rather than muscle, supporting an indirect neural relay to skeletal muscle.
- Eight months of treatment improved several functional measures in mainly male aged mice without increasing muscle mass.
- The human study used one 25 mg dose and found only a short-term eNAMPT signal in selected middle-aged subgroups.
Verdict. This is strong mechanistic mouse evidence and an early human biomarker observation, not proof of an anti-frailty supplement for people.
The findingA fat-to-brain-to-muscle signal
Researchers identified a pathway in which S-1-propenyl-L-cysteine (S1PC), a compound found in aged garlic extract, prompts white adipose tissue to release extracellular vesicles containing eNAMPT. Those vesicles travel through the blood and act on the hypothalamus, which can then influence skeletal muscle through neural signaling.
The proposed sequence is specific: S1PC helps LKB1 form its active complex with STRAD and MO25, LKB1 increases SIRT1 phosphorylation, and SIRT1 promotes eNAMPT secretion from white fat. In mice, circulating eNAMPT and hypothalamic NAD+ rose after oral S1PC.
The muscle did not appear to receive the fat-derived vesicles directly; the hypothalamus acted as the relay.
MechanismWhy the hypothalamus matters
Tracing experiments detected tagged fat-derived NAMPT in the hypothalamus but not in skeletal muscle. The study therefore links improved muscle function to an inter-organ circuit rather than a direct effect of S1PC on muscle fibers.
The downstream pattern was consistent with stronger sympathetic and beta-adrenergic signaling to muscle: treated aged mice showed higher muscle CREB phosphorylation and changes in oxidative-phosphorylation proteins. When adipose Nampt was deleted, S1PC no longer improved muscle force, supporting a causal role for fat-derived eNAMPT.
Mouse evidenceEight months of treatment
The long-term study began when C57BL/6J mice were 15 months old and continued until 23 months. S1PC-treated animals had lower frailty-index scores, stronger muscle force during high-frequency electrical stimulation, and improved grip strength. Their plantar-flexor muscle mass did not increase, so the result was functional rather than evidence of larger muscles.
| Frailty index | Lower in treated aged mice. |
|---|---|
| Muscle force | Higher during high-frequency stimulation; single-twitch force was not significantly different. |
| Grip strength | Improved in treated mice. |
| Muscle mass | No meaningful increase. |
| Study population | Mechanistic work relied primarily on male mice. |
Human evidenceA biomarker study, not a strength trial
Forty healthy Japanese adults aged 20–49 completed a randomized, double-blind, placebo-controlled experiment. Nineteen received garlic powder containing 25 mg of S1PC and 21 received placebo. Blood was sampled before dosing and at 30, 60, and 120 minutes.
Across participants with BMI at least 18.5, the groups did not differ significantly in circulating eNAMPT. A significant rise appeared after the researchers separated age groups and examined participants in their forties who also maintained specified BMI or body-fat-mass thresholds. That narrower, post-stratified result needs confirmation in a larger study with subgroups defined in advance.
LimitsWhat still has to be tested
- 1. Human outcomes: Long-term trials must measure muscle performance and frailty directly.
- 2. Sex differences: Most animal experiments used males, so responses in females remain uncertain.
- 3. Neural target: The exact hypothalamic cell populations responding to eNAMPT vesicles are unknown.
- 4. Replication: Several authors are affiliated with Wakunaga Pharmaceutical; the authors also disclose a provisional patent and an S1PC trademark relationship.
The paper provides a coherent preclinical mechanism, not a dosing guide. Ordinary garlic, aged garlic extract, concentrated powder and purified S1PC are not equivalent exposures. The useful next step is an independently replicated, preregistered human trial, not self-supplementation based on the mouse dose.